Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung Cancer

David R Gandara; Jonathan W Riess; Karen Kelly; Tianhong Li; Philip C Mack; Primo N Lara Jr

doi:10.1016/j.cllc.2016.12.011

Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung Cancer

Clin Lung Cancer. 2017 Jan;18(1):1-4. doi: 10.1016/j.cllc.2016.12.011. Epub 2016 Dec 24.

Authors

David R Gandara¹, Jonathan W Riess², Karen Kelly², Tianhong Li², Philip C Mack², Primo N Lara Jr²

Affiliations

¹ University of California, Davis, Comprehensive Cancer Center, Sacramento, CA. Electronic address: [email protected].
² University of California, Davis, Comprehensive Cancer Center, Sacramento, CA.

PMID: 28082049
DOI: 10.1016/j.cllc.2016.12.011

Abstract

The therapeutic landscape in advanced non-small-cell lung cancer (NSCLC) is rapidly changing. Never have so many changes of major importance occurred within so short a time. The present perspective describes this rapid evolution and resultant increasing complexity in the therapeutic decision-making process for the practicing oncologist.

Keywords: Epidermal growth factor receptor; NSCLC; Targeted therapy; Therapeutic landscape; Tyrosine kinase inhibitor.

MeSH terms

Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / pathology
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Molecular Targeted Therapy*
Prognosis
Protein Kinase Inhibitors / therapeutic use*
Receptor Protein-Tyrosine Kinases / antagonists & inhibitors*

Substances

Protein Kinase Inhibitors
Receptor Protein-Tyrosine Kinases